BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu L, Wei Q, Brzostek J, Gascoigne NRJ. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells. Cell Mol Immunol 2020;17:600-12. [PMID: 32451454 DOI: 10.1038/s41423-020-0470-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Kouakanou L, Peters C, Brown CE, Kabelitz D, Wang LD. Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy? Front Immunol 2021;12:765906. [PMID: 34899716 DOI: 10.3389/fimmu.2021.765906] [Reference Citation Analysis]
2 Venetis K, Invernizzi M, Sajjadi E, Curigliano G, Fusco N. Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. Cancer Treat Rev 2020;90:102089. [PMID: 32889360 DOI: 10.1016/j.ctrv.2020.102089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Feola S, Russo S, Ylösmäki E, Cerullo V. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol Ther 2021;236:108103. [PMID: 34954301 DOI: 10.1016/j.pharmthera.2021.108103] [Reference Citation Analysis]
4 Kent A, Longino NV, Christians A, Davila E. Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy. Front Immunol 2021;12:658611. [PMID: 34012443 DOI: 10.3389/fimmu.2021.658611] [Reference Citation Analysis]
5 Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, Mog BJ, Bettegowda C, Pardoll DM, Gabelli SB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Targeting public neoantigens for cancer immunotherapy. Nat Cancer 2021;2:487-97. [PMID: 34676374 DOI: 10.1038/s43018-021-00210-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
6 Khanali J, Azangou-Khyavy M, Boroomand-Saboor M, Ghasemi M, Niknejad H. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment. Front Immunol 2021;12:638639. [PMID: 34177890 DOI: 10.3389/fimmu.2021.638639] [Reference Citation Analysis]
7 Chandler NJ, Call MJ, Call ME. T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors. Int J Mol Sci 2020;21:E7424. [PMID: 33050044 DOI: 10.3390/ijms21197424] [Reference Citation Analysis]
8 Zhang Y, Wei Y, Jiang S, Dang Y, Yang Y, Zuo W, Zhu Q, Liu P, Gao Y, Lu S. Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling. Phytomedicine 2022;99:153939. [DOI: 10.1016/j.phymed.2022.153939] [Reference Citation Analysis]
9 Quintarelli C, Camera A, Ciccone R, Alessi I, Del Bufalo F, Carai A, Del Baldo G, Mastronuzzi A, De Angelis B. Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We? Front Immunol 2021;12:634031. [PMID: 34163465 DOI: 10.3389/fimmu.2021.634031] [Reference Citation Analysis]
10 Griffith AA, Callahan KP, King NG, Xiao Q, Su X, Salomon AR. SILAC Phosphoproteomics Reveals Unique Signaling Circuits in CAR-T Cells and the Inhibition of B Cell-Activating Phosphorylation in Target Cells. J Proteome Res 2022. [PMID: 35014847 DOI: 10.1021/acs.jproteome.1c00735] [Reference Citation Analysis]
11 Kramer MM, Lataster L, Weber W, Radziwill G. Optogenetic Approaches for the Spatiotemporal Control of Signal Transduction Pathways. Int J Mol Sci 2021;22:5300. [PMID: 34069904 DOI: 10.3390/ijms22105300] [Reference Citation Analysis]
12 Karachi A, Dastmalchi F, Nazarian S, Huang J, Sayour EJ, Jin L, Yang C, Mitchell DA, Rahman M. Optimizing T Cell-Based Therapy for Glioblastoma. Front Immunol 2021;12:705580. [PMID: 34421912 DOI: 10.3389/fimmu.2021.705580] [Reference Citation Analysis]
13 Alfei F, Ho PC, Lo WL. DCision-making in tumors governs T cell anti-tumor immunity. Oncogene 2021. [PMID: 34290401 DOI: 10.1038/s41388-021-01946-8] [Reference Citation Analysis]
14 Sun S, Ding Z, Yang X, Zhao X, Zhao M, Gao L, Chen Q, Xie S, Liu A, Yin S, Xu Z, Lu X. Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy. Int J Nanomedicine 2021;16:2337-56. [PMID: 33790553 DOI: 10.2147/IJN.S297631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hossain NM, Stiff PJ. Expanding the Toolbox of Adoptive Cell Immunotherapy. J Clin Oncol 2021;39:1479-82. [PMID: 33764792 DOI: 10.1200/JCO.21.00295] [Reference Citation Analysis]
16 Wei Q, Brzostek J, Sankaran S, Casas J, Hew LS, Yap J, Zhao X, Wojciech L, Gascoigne NRJ. Lck bound to coreceptor is less active than free Lck. Proc Natl Acad Sci U S A 2020;117:15809-17. [PMID: 32571924 DOI: 10.1073/pnas.1913334117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
17 Lo WL, Weiss A. Adapting T Cell Receptor Ligand Discrimination Capability via LAT. Front Immunol 2021;12:673196. [PMID: 33936119 DOI: 10.3389/fimmu.2021.673196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Mardi A, Shirokova AV, Mohammed RN, Keshavarz A, Zekiy AO, Thangavelu L, Mohamad TAM, Marofi F, Shomali N, Zamani A, Akbari M. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int 2022;22:168. [PMID: 35488303 DOI: 10.1186/s12935-022-02585-z] [Reference Citation Analysis]
19 Webster B, Xiong Y, Hu P, Wu D, Alabanza L, Orentas RJ, Dropulic B, Schneider D. Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models. Mol Ther 2021;29:2691-706. [PMID: 33974997 DOI: 10.1016/j.ymthe.2021.05.006] [Reference Citation Analysis]
20 Krzysztoń R, Wan Y, Petreczky J, Balázsi G. Gene-circuit therapy on the horizon: synthetic biology tools for engineered therapeutics. Acta Biochim Pol 2021;68:377-83. [PMID: 34460209 DOI: 10.18388/abp.2020_5744] [Reference Citation Analysis]
21 Mao R, Hussein MS, He Y. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours. Expert Rev Mol Med 2022;24:e7. [PMID: 35086597 DOI: 10.1017/erm.2021.32] [Reference Citation Analysis]
22 Kimmel GJ, Locke FL, Altrock PM. The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. Proc Biol Sci 2021;288:20210229. [PMID: 33757357 DOI: 10.1098/rspb.2021.0229] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Atsavapranee ES, Billingsley MM, Mitchell MJ. Delivery technologies for T cell gene editing: Applications in cancer immunotherapy. EBioMedicine 2021;67:103354. [PMID: 33910123 DOI: 10.1016/j.ebiom.2021.103354] [Reference Citation Analysis]
24 Li R, Ma C, Cai H, Chen W. The CAR T-Cell Mechanoimmunology at a Glance. Adv Sci (Weinh) 2020;7:2002628. [PMID: 33344135 DOI: 10.1002/advs.202002628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Janssens I, Cools N. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity? Cell Immunol 2020;358:104236. [PMID: 33137651 DOI: 10.1016/j.cellimm.2020.104236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Banik D, Hamidinia M, Brzostek J, Wu L, Stephens HM, MacAry PA, Reinherz EL, Gascoigne NRJ, Lang MJ. Single Molecule Force Spectroscopy Reveals Distinctions in Key Biophysical Parameters of αβ T-Cell Receptors Compared with Chimeric Antigen Receptors Directed at the Same Ligand. J Phys Chem Lett 2021;12:7566-73. [PMID: 34347491 DOI: 10.1021/acs.jpclett.1c02240] [Reference Citation Analysis]
27 Wu L, Brzostek J, Sankaran S, Wei Q, Yap J, Tan TYY, Lai J, MacAry PA, Gascoigne NRJ. Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell Model. Cancers (Basel) 2021;13:867. [PMID: 33670734 DOI: 10.3390/cancers13040867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ereño-Orbea J, Liu X, Sicard T, Kucharska I, Li W, Borovsky D, Cui H, Feng Y, Dimitrov DS, Julien JP. Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22. J Biol Chem 2021;297:100966. [PMID: 34273351 DOI: 10.1016/j.jbc.2021.100966] [Reference Citation Analysis]
29 Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov 2021;20:531-50. [PMID: 33972771 DOI: 10.1038/s41573-021-00189-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
30 Harris MJ, Fuyal M, James JR. Quantifying persistence in the T-cell signaling network using an optically controllable antigen receptor. Mol Syst Biol 2021;17:e10091. [PMID: 33988299 DOI: 10.15252/msb.202010091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. ACS Nano 2021. [PMID: 34339170 DOI: 10.1021/acsnano.1c02103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Ivica NA, Young CM. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997-2020). Healthcare (Basel) 2021;9:1062. [PMID: 34442199 DOI: 10.3390/healthcare9081062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zhang C, Hu Y, Xiao W, Tian Z. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol 2021. [PMID: 34267335 DOI: 10.1038/s41423-021-00732-6] [Reference Citation Analysis]